Velussi et al[25] reckoned that SIL (silymarin 600 mg/day, 12 months) enhanced the endogenous and exogenous insulin sensitivities directly, which suggested an interesting regimen for NAFLD. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.